EverSource Wealth Advisors LLC Boosts Stock Holdings in Boston Scientific Co. (NYSE:BSX)

EverSource Wealth Advisors LLC lifted its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 17.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,850 shares of the medical equipment provider’s stock after buying an additional 421 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Boston Scientific were worth $255,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Sequoia Financial Advisors LLC grew its position in shares of Boston Scientific by 14.7% in the fourth quarter. Sequoia Financial Advisors LLC now owns 30,271 shares of the medical equipment provider’s stock valued at $2,704,000 after purchasing an additional 3,879 shares in the last quarter. Wealth High Governance Capital Ltda purchased a new position in Boston Scientific during the 4th quarter valued at about $4,444,000. Fairway Wealth LLC bought a new stake in shares of Boston Scientific during the fourth quarter valued at about $36,000. Citizens Financial Group Inc. RI lifted its holdings in shares of Boston Scientific by 78.0% in the fourth quarter. Citizens Financial Group Inc. RI now owns 8,970 shares of the medical equipment provider’s stock worth $801,000 after buying an additional 3,931 shares in the last quarter. Finally, Sage Mountain Advisors LLC boosted its position in shares of Boston Scientific by 12.5% in the fourth quarter. Sage Mountain Advisors LLC now owns 7,417 shares of the medical equipment provider’s stock valued at $663,000 after acquiring an additional 822 shares during the period. 89.07% of the stock is owned by institutional investors.

Boston Scientific Trading Up 2.0 %

NYSE BSX opened at $97.26 on Friday. The firm has a market cap of $143.53 billion, a PE ratio of 77.81, a price-to-earnings-growth ratio of 2.79 and a beta of 0.77. Boston Scientific Co. has a 1-year low of $66.16 and a 1-year high of $107.17. The stock has a 50-day moving average of $101.05 and a 200-day moving average of $91.76. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. As a group, sell-side analysts forecast that Boston Scientific Co. will post 2.85 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the completion of the sale, the executive vice president now directly owns 5,502 shares in the company, valued at approximately $560,103.60. This represents a 75.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of the company’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $104.25, for a total value of $487,368.75. Following the transaction, the executive vice president now directly owns 28,454 shares of the company’s stock, valued at $2,966,329.50. The trade was a 14.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 137,302 shares of company stock valued at $14,319,269 in the last quarter. Insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Royal Bank of Canada increased their target price on shares of Boston Scientific from $105.00 to $116.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. JPMorgan Chase & Co. increased their price objective on Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a research report on Monday, December 16th. TD Cowen boosted their target price on Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, December 12th. Truist Financial raised their price target on Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. Finally, Raymond James boosted their price objective on Boston Scientific from $119.00 to $122.00 and gave the stock a “strong-buy” rating in a report on Thursday, February 6th. Two equities research analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $108.91.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.